학술논문
Intravitreal Ziv-Aflibercept in Patients With Diabetic Macular Edema Refractory to Intravitreal Bevacizumab
Document Type
Clinical report
Author
Source
Ophthalmic Surgery, Lasers, and Imaging Retina. March, 2020, Vol. 51 Issue 3, p145, 7 p.
Subject
Language
English
ISSN
2325-8160
Abstract
BACKGROUND AND OBJECTIVE: To evaluate the efficacy of intravitreal ziv-aflibercept (IVZ) in patients with diabetic macular edema (DME) resistant to intravitreal bevacizumab (IVB). PATIENTS AND METHODS: This prospective study was conducted in patients with persistent DME. Patients were switched to IVZ no longer than 6 weeks after the last three consecutive monthly IVB treatments and monitored over a course of 12 weeks. Changes in best-corrected visual acuity (BCVA), central macular thickness (CMT), and macular volume on optical coherence tomography were compared. RESULTS: A total of 59 eyes (38 patients) were included. Mean BCVA improved from 0.84 to 0.71 logMAR (P =.001) after first IVZ treatment and remained significant. In a subgroup analysis, this significance was observed only in the group with baseline visual acuity of less than 20/50. Mean CMT decreased from 479 μm to 364 μm (P =.004) after the first IVZ injections and remained significant. CONCLUSION: IVZ may be best reserved for patients with persistent DME after initial failure with bevacizumab, with less likelihood for anatomic or functional improvement in those with mild persistent DME. [Ophthalmic Surg Lasers Imaging Retina. 2020;51:145–151.]
Introduction Diabetic macular edema (DME) affects 20% to 40% of patients with diabetes over a 10- to 20-year period and is a leading cause of vision loss globally. (1) The [...]
Introduction Diabetic macular edema (DME) affects 20% to 40% of patients with diabetes over a 10- to 20-year period and is a leading cause of vision loss globally. (1) The [...]